Liver Cancer in China
Overview
Primary liver cancer — hepatocellular carcinoma (HCC) — usually arises in cirrhotic livers damaged by hepatitis B or C. China treats the world’s largest HCC population, and its leading liver centers offer every modality at high volume: resection, ablation, transarterial therapy, transplantation and systemic treatment.
A distinctive strength of Chinese programs is conversion therapy — combining targeted and immunotherapy to shrink advanced tumors until they become operable.
Symptoms & Signs
Right upper abdominal pain or a sensation of fullness
Unintentional weight loss and early satiety
Jaundice or abdominal swelling from fluid accumulation in advanced disease
Fatigue and general deterioration in cirrhotic patients
Often detected by ultrasound and AFP surveillance of cirrhosis before symptoms appear
New decompensation of known cirrhosis — ascites, confusion or bleeding — warranting urgent imaging
Diagnosis
Multiphase contrast CT and MRI with LI-RADS criteria characterizing the lesion
Serum AFP and newer biomarkers such as AFP-L3 and DCP
Liver function assessment (Child-Pugh, ALBI) essential for choosing safe treatment
Biopsy when imaging is inconclusive or non-HCC pathology is suspected
Hepatitis B and C serology guiding antiviral management alongside cancer therapy
FibroScan elastography assessing underlying liver stiffness
Treatment Options
Surgical resection for tumors in well-preserved livers, increasingly laparoscopic or robotic
Thermal ablation (radiofrequency or microwave) for small tumors with curative intent
TACE transarterial chemoembolization for intermediate-stage disease
Liver transplantation for selected patients within transplant criteria
Systemic therapy with targeted and immune checkpoint inhibitors for advanced disease
Conversion therapy downstaging tumors to resectable or transplantable status
Advanced Technologies & Novel Drug
Laparoscopic and robotic hepatectomy with ICG fluorescence guidance
Image-navigated ablation fusing ultrasound and CT for precise needle placement
Drug-eluting-bead TACE delivering chemotherapy directly to the tumor
ALPPS staged hepatectomy expanding resectability in marginal livers
Novel first-line targeted-immunotherapy combinations available at Chinese liver centers
Hospital & Specialist
- Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS) — Beijing
- Zhongshan Hospital, Fudan University — Shanghai
- Sun Yat-sen University Cancer Center (SYSUCC) — Guangzhou
- West China Hospital, Sichuan University (Huaxi Hospital) — Chengdu
- Li Qiang — Hepatobiliary Oncology
- Li Qiang — Hepatobiliary Oncology
- Sang Xin Ting — Liver Surgery
- Mao Yi Lei — Liver Surgery